BioSpace News Archive

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, today announced that its management will present at the Raymond James 42nd Annual Institutional Investors Conference on Monday, March 1, 2021 at 1:20 p.m. E.T.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, to provide phlebotomy services to support Galleri™, GRAIL’s multi-cancer early detection blood test.

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has launched its new Glaucoma Module feature for the Harmony Clinical Data Management Solution.

Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that senior management will participate in two upcoming virtual healthcare investor conferences.

- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond James 42 nd Annual Institutional Investors Conference and the Barclays Global Healthcare Conference in March.

Teligent, Inc. (Nasdaq: TLGT), (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences: The Cowen 41 st Annual Virtual Health Care Conference.

Progenity, Inc. announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock and warrants to purchase common stock, as described below, in a private placement expected to result in gross proceeds to Progenity of approximately $25 million, before deducting placement agent commissions and other offering expenses.

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for a pilot study evaluating the company’s lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in progressive multifocal leukoencephalopathy (PML).

TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) in oncology, today announced the appointment of Brian M. Silver as its Chief Financial Officer, effective May 2, 2021. Mr. Silver brings to TScan over 25 years of diverse strategic and financial experience within the healthcare and investment banking sectors.